Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
APO-EPO
(epoetin alfa biosimilar) /
Apotex
Welcome,
Profile
Billing
Logout
0 Diseases
1 Trial
1 Trial
5 News
|
|||||||||
APO-EPO
(epoetin alfa biosimilar) /
Apotex
Trial initiation date:
Study of safety and efficacy of APO-EPO versus US licensed Procrit
(EUDRACT) - Apr 16, 2013
P3
, N=552, Ongoing,
Sponsor: APOTEX Inc.
Initiation date: Oct 2012 --> Feb 2013
|
|||||||||
APO-EPO
(epoetin alfa biosimilar) /
Apotex
Enrollment change:
Study of safety and efficacy of APO-EPO versus US licensed Procrit
(EUDRACT) - Apr 16, 2013
P3
, N=552, Ongoing,
Sponsor: APOTEX Inc.
Initiation date: Oct 2012 --> Feb 2013 N=37 --> 552
||||||||||
APO-EPO
(epoetin alfa biosimilar) /
Apotex
PK/PD data, Trial termination:
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysis
(EUDRACT) - Apr 2, 2013
P3
, N=196, Terminated,
Sponsor: APOTEX Inc.
N=37 --> 552 Ongoing --> Terminated
||||||||||
APO-EPO
(epoetin alfa biosimilar) /
Apotex
New P3 trial, PK/PD data:
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysis
(EUDRACT) - Jan 10, 2013
P3
, N=196, Terminated,
Sponsor: APOTEX Inc.
||
||||||||
APO-EPO
(epoetin alfa biosimilar) /
Apotex
New P3 trial:
Study of safety and efficacy of APO-EPO versus US licensed Procrit
(EUDRACT) - Aug 5, 2012
P3
, N=552, Ongoing,
Sponsor: APOTEX Inc.